58. Per Med. 2017 May;14(3):213-220. doi: 10.2217/pme-2016-0091. Epub 2017 Mar 29.Optimization of quality assurance to increase clinical utility and costeffectiveness of hereditary cancer testing.Smith S(1), Marino I(1), Schaller J(1), Arnell C(1), Moyes K(1), Manley S(1).Author information: (1)Myriad Genetic Laboratories, Inc., Salt Lake City, UT, USA.AIM: To evaluate one laboratory's hereditary cancer testing clinical qualityassurance (QA) process to minimize test-ordering errors.METHODS: The proportion of tests canceled/revised due to pre-analytic QAprocesses or provider consultation prior to test ordering were determined and theresulting health cost savings were estimated.RESULTS: Over 2000 genetic test orders were canceled/revised over a 1-year perioddue to the laboratory QA process, saving US$5,801,832 in healthcare costs.Consultation with healthcare providers prior to submitting genetic test requests resulted in 37 canceled/revised test orders in a 2-week period, whichextrapolates to a savings of US$3,049,098 over 1 year.CONCLUSION: QA processes can contribute to the curtailment of healthcare coststhrough canceling or revising test orders.DOI: 10.2217/pme-2016-0091 PMID: 29767585 